The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We investigated whether the quantification of hepatitis surface antigen (HBsAg) could predict HBsAg loss or hepatitis B virus (HBV) relapse after stopping lamivudine treatment.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Hepatol.

Title: Journal of hepatology

ISSN (Electronic): 1600-0641

ISSN (Print): 0168-8278

Publication date (Electronic): Sep 2014

Volume: 61

Issue: 3

Affiliations

[1 ] Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

[2 ] Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Electronic address: chmolee88@gmail.com.

Article

Publisher Item ID: S0168-8278(14)00292-X

DOI: 10.1016/j.jhep.2014.04.029

PubMed ID: 24798617

SO-VID: dc634205-1764-4afb-8af9-f6813f8d89ca

History

Keywords: HBV relapse,HBeAg seroconversion,Hepatitis B surface antigen,Hepatitis B virus

Data availability:

Keywords: HBV relapse, HBeAg seroconversion, Hepatitis B surface antigen, Hepatitis B virus

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.

Read this article at

Abstract

Related collections

Point-Of-Care Testing for Hepatitis

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 51

Cited by 50